Loading organizations...
Innovac Therapeutics is a biotechnology company developing innovative vaccines and therapeutics using proprietary mRNA technology platforms, based in Cambridge, Massachusetts. The company focuses on addressing unmet medical needs in infectious diseases and cancer, operating as a venture-backed biotech in the early-stage funding phase. Innovac Therapeutics secured $18 million in pre-seed funding (Series Pre-A) in August 2023 to advance its lead program, INV001, and expand manufacturing capabilities. With an employee count ranging from 11 to 50, key investors include Elikon Venture, Vision Plus Capital, Yunion Healthcare Ventures, and TG Sino-Dragon Fund. The company was founded in 2022 by experienced industry veterans Michael (Chi) Zhang, MD, Nicholas Valiante, PhD, and Hang Yuan, PhD. Its business model centers on venture-backed biotech company operating in the seed/early-stage funding phase, raising capital to fund drug development and manufacturing capabilities.
Innovac Therapeutics has raised $18.0M across 1 funding round.
Innovac Therapeutics has raised $18.0M in total across 1 funding round.
Innovac Therapeutics has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Pre-Series A in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 4, 2023 | $18M Seed Plus | — | TG Sino Dragon Fund, Vision Plus Capital, Yunion Healthcare Ventures | Announced |
Innovac Therapeutics has raised $18.0M in total across 1 funding round.
Innovac Therapeutics's investors include TG Sino-Dragon Fund, Vision Plus Capital, Yunion Healthcare Ventures.
